Moberg Pharma AB
MB8
Company Profile
Business description
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company’s main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
Contact
Gustavslundsvagen 42
5th Floor, Bromma
StockholmSE-167 51
SWET: +46 852230700
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
9
Stocks News & Analysis
stocks
Westpac earnings: Tech overhaul is costly but not hurting lending and deposit growth
Our view after latest earnings report.
stocks
Berkshire Hathaway earnings: Cash balances hit $358 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is moderately undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,150.10 | 23.90 | -0.26% |
| CAC 40 | 8,109.79 | 11.28 | -0.14% |
| DAX 40 | 24,132.41 | 174.11 | 0.73% |
| Dow JONES (US) | 47,336.68 | 226.19 | -0.48% |
| FTSE 100 | 9,701.37 | 15.88 | -0.16% |
| HKSE | 26,158.36 | 251.71 | 0.97% |
| NASDAQ | 23,834.72 | 109.77 | 0.46% |
| Nikkei 225 | 52,294.31 | 117.03 | -0.22% |
| NZX 50 Index | 13,643.86 | 87.56 | 0.65% |
| S&P 500 | 6,851.97 | 11.77 | 0.17% |
| S&P/ASX 200 | 8,863.60 | 19.10 | -0.22% |
| SSE Composite Index | 3,976.52 | 21.73 | 0.55% |